Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2019-09-02 Board/Management Inform…
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT : Au nom du Conseil d’Administration, son Président Jean-François Mouney annonce la nomination de Pascal Prigent au poste de nouveau Directeur Général
Board/Management Information Classification · 100% confidence The document is a press release from GENFIT announcing the appointment of a new CEO (Pascal Prigent) and the transition of the co-founder (Jean-François Mouney) to the role of Chairman of the Board. This falls under the category of board and management changes. Although it includes a link to a PDF attachment, the text itself provides the full details of the announcement, making it a primary announcement rather than just a notification of a report.
2019-09-02 French
GENFIT: Board of Directors, Represented by Chairman Jean-François Mouney, Appoints Pascal Prigent as New CEO
Board/Management Information Classification · 98% confidence The document is a press release announcing the appointment of a new CEO and changes to the Board of Directors at GENFIT. While it contains information about management changes, it is a formal corporate announcement rather than a standalone regulatory filing for board changes. However, per the provided definitions, 'MANG' is specifically for the announcement of changes in the board or senior management. The document is clearly an announcement of these specific personnel changes.
2019-09-02 English
GENFIT : Au nom du Conseil d’Administration, son Président Jean-François Mouney annonce la nomination de Pascal Prigent au poste de nouveau Directeur Général
Board/Management Information Classification · 98% confidence The document is a press release dated September 2, 2019, announcing a change in senior management: the appointment of Pascal Prigent as the new CEO, succeeding the co-founder Jean-François Mouney, who remains Chairman of the Board. This content directly relates to changes in the company's senior management team. This aligns perfectly with the definition for Board/Management Information (MANG). Although it is a press release, the core subject matter is management change, which is more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA). The document length (13,825 chars) is substantial, indicating it is the primary announcement, not just a notification that a report is attached.
2019-09-02 French
GENFIT: Board of Directors, Represented by Chairman Jean-François Mouney, Appoints Pascal Prigent as New CEO
Board/Management Information Classification · 100% confidence The document is a press release dated September 2, 2019, announcing a significant change in senior management: the appointment of Pascal Prigent as the new CEO, while the co-founder Jean-François Mouney transitions to Chairman of the Board. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2019-09-02 English
GENFIT : Au nom du Conseil d’Administration, son Président Jean-François Mouney annonce la nomination de Pascal Prigent au poste de nouveau Directeur Général
Board/Management Information Classification · 100% confidence The document is a press release dated September 2, 2019, announcing a significant change in senior management: the appointment of Pascal Prigent as the new Chief Executive Officer (Directeur Général) and Jean-François Mouney stepping into the role of Chairman of the Board. This content directly relates to changes in the company's senior leadership team. According to the definitions, this falls under 'Board/Management Information' (Code: MANG). It is not an earnings release (ER), a full annual report (10-K), or a proxy statement (DEF 14A/PSI).
2019-09-02 French
GENFIT: FDA and EMA Grant GENFIT’s Elafibranor Orphan Drug Designation for Primary Biliary Cholangitis (PBC)
Regulatory Filings Classification · 95% confidence The document is a press release dated July 29, 2019, announcing that GENFIT's drug candidate, elafibranor, received Orphan Drug Designation from the FDA and EMA for treating Primary Biliary Cholangitis (PBC). It discusses clinical trial results (Phase 2 data) and future plans (Phase 3 trial launch). This type of announcement, detailing significant regulatory milestones, clinical data updates, and future development plans, is characteristic of an Earnings Release (ER) or a general press release announcing corporate/pipeline progress. Since it is not a full annual report (10-K), a formal quarterly report (IR), a transcript (CT), or a specific financial filing like a proxy statement (DEF 14A), the most appropriate classification for a major, time-sensitive corporate update that is not a formal financial statement is Earnings Release (ER), as these often contain key operational and pipeline highlights, or Regulatory Filing (RNS) if it were less specific. Given the focus on regulatory milestones (Orphan Drug Designation) and clinical data summaries, it functions as a high-level corporate update, which often falls under ER if it's not tied to a specific quarterly financial report, or RNS as a general regulatory announcement. However, since it is a detailed announcement of a major regulatory event and clinical progress, and not just a brief notice of report publication, ER is a strong candidate if it's near an earnings period, but RNS is the safest general regulatory announcement category. Given the context of major drug development news, and the lack of explicit quarterly financial tables, I will lean towards RNS as the general regulatory announcement fallback, as it is a press release detailing regulatory actions and clinical progress, which fits the broad 'Regulatory Filings' category when specific operational/financial report codes don't apply perfectly. Upon review, this is a standard press release announcing regulatory and clinical progress, which is often categorized as RNS (Regulatory News Service/General Regulatory Announcement) when it doesn't fit the specific financial report types.
2019-07-29 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.